David R Taylor1, Lea Ghataore2, Lewis Couchman2,3, Royce P Vincent2, Ben Whitelaw4, Dylan Lewis5, Salvador Diaz-Cano6, Gabriele Galata7, Klaus-Martin Schulte7, Simon Aylwin4, Norman F Taylor2. 1. Department of Clinical Biochemistry (Viapath), King's College Hospital NHS Foundation Trust, London, UK; davidtaylor8@nhs.net. 2. Department of Clinical Biochemistry (Viapath), King's College Hospital NHS Foundation Trust, London, UK. 3. Department of Toxicology (Viapath), King's College Hospital NHS Foundation Trust, London, UK. 4. Department of Endocrinology, King's College Hospital NHS Foundation Trust, London, UK. 5. Department of Radiology, King's College Hospital NHS Foundation Trust, London, UK. 6. Department of Histopathology, King's College Hospital NHS Foundation Trust, London, UK. 7. Department of Surgery, King's College Hospital NHS Foundation Trust, London, UK.
Abstract
BACKGROUND: Adrenocortical carcinoma (ACC) is a rare malignancy, with an annual incidence of 1 or 2 cases per million. Biochemical diagnosis is challenging because up to two-thirds of the carcinomas are biochemically silent, resulting from de facto enzyme deficiencies in steroid hormone biosynthesis. Urine steroid profiling by GC-MS is an effective diagnostic test for ACC because of its capacity to detect and quantify the increased metabolites of steroid pathway synthetic intermediates. Corresponding serum assays for most steroid pathway intermediates are usually unavailable because of low demand or lack of immunoassay specificity. Serum steroid analysis by LC-MS/MS is increasingly replacing immunoassay, in particular for steroids most subject to cross-reaction. METHODS: We developed an LC-MS/MS method for the measurement of serum androstenedione, corticosterone, cortisol, cortisone, 11-deoxycorticosterone, 11-deoxycortisol, 21-deoxycortisol, dehydroepiandrosterone sulfate, pregnenolone, 17-hydroxypregnenolone, progesterone, 17-hydroxyprogesterone, and testosterone. Assay value in discriminating ACC from other adrenal lesions (phaeochromocytoma/paraganglioma, cortisol-producing adenoma, and lesions demonstrating no hormonal excess) was then investigated. RESULTS: In ACC cases, between 4 and 7 steroids were increased (median = 6), and in the non-ACC groups, up to 2 steroids were increased. 11-Deoxycortisol was markedly increased in all cases of ACC. All steroids except testosterone in males and corticosterone and cortisone in both sexes were of use in discriminating ACC from non-ACC adrenal lesions. CONCLUSIONS: Serum steroid paneling by LC-MS/MS is useful for diagnosing ACC by combining the measurement of steroid hormones and their precursors in a single analysis.
BACKGROUND:Adrenocortical carcinoma (ACC) is a rare malignancy, with an annual incidence of 1 or 2 cases per million. Biochemical diagnosis is challenging because up to two-thirds of the carcinomas are biochemically silent, resulting from de facto enzyme deficiencies in steroid hormone biosynthesis. Urine steroid profiling by GC-MS is an effective diagnostic test for ACC because of its capacity to detect and quantify the increased metabolites of steroid pathway synthetic intermediates. Corresponding serum assays for most steroid pathway intermediates are usually unavailable because of low demand or lack of immunoassay specificity. Serum steroid analysis by LC-MS/MS is increasingly replacing immunoassay, in particular for steroids most subject to cross-reaction. METHODS: We developed an LC-MS/MS method for the measurement of serum androstenedione, corticosterone, cortisol, cortisone, 11-deoxycorticosterone, 11-deoxycortisol, 21-deoxycortisol, dehydroepiandrosterone sulfate, pregnenolone, 17-hydroxypregnenolone, progesterone, 17-hydroxyprogesterone, and testosterone. Assay value in discriminating ACC from other adrenal lesions (phaeochromocytoma/paraganglioma, cortisol-producing adenoma, and lesions demonstrating no hormonal excess) was then investigated. RESULTS: In ACC cases, between 4 and 7 steroids were increased (median = 6), and in the non-ACC groups, up to 2 steroids were increased. 11-Deoxycortisol was markedly increased in all cases of ACC. All steroids except testosterone in males and corticosterone and cortisone in both sexes were of use in discriminating ACC from non-ACC adrenal lesions. CONCLUSIONS: Serum steroid paneling by LC-MS/MS is useful for diagnosing ACC by combining the measurement of steroid hormones and their precursors in a single analysis.
Authors: Thomas G Papathomas; Na Sun; Vasileios Chortis; Angela E Taylor; Wiebke Arlt; Susan Richter; Graeme Eisenhofer; Gerard Ruiz-Babot; Leonardo Guasti; Axel Karl Walch Journal: Histochem Cell Biol Date: 2019-02-06 Impact factor: 4.304
Authors: Karl-Heinz Storbeck; Lina Schiffer; Elizabeth S Baranowski; Vasileios Chortis; Alessandro Prete; Lise Barnard; Lorna C Gilligan; Angela E Taylor; Jan Idkowiak; Wiebke Arlt; Cedric H L Shackleton Journal: Endocr Rev Date: 2019-12-01 Impact factor: 19.871
Authors: Mark Sherlock; Andrew Scarsbrook; Afroze Abbas; Sheila Fraser; Padiporn Limumpornpetch; Rosemary Dineen; Paul M Stewart Journal: Endocr Rev Date: 2020-12-01 Impact factor: 19.871
Authors: Gerard Ruiz-Babot; Mariya Balyura; Irene Hadjidemetriou; Sharon J Ajodha; David R Taylor; Lea Ghataore; Norman F Taylor; Undine Schubert; Christian G Ziegler; Helen L Storr; Maralyn R Druce; Evelien F Gevers; William M Drake; Umasuthan Srirangalingam; Gerard S Conway; Peter J King; Louise A Metherell; Stefan R Bornstein; Leonardo Guasti Journal: Cell Rep Date: 2018-01-30 Impact factor: 9.423